XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Accounting Policies, Revenue Recognition (Details)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
USD ($)
Target
Jun. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2018
USD ($)
Jun. 30, 2018
Agreement
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Component
PerformanceObligation
Revenue Recognition [Abstract]                    
Revenue $ 159,767     $ 133,093       $ 435,478 $ 370,450  
Biogen [Member]                    
Revenue Recognition [Abstract]                    
Number of agreements | Agreement             2      
2013 Strategic Neurology Collaboration with Biogen [Member] | ION859 [Member]                    
Revenue Recognition [Abstract]                    
Revenue     $ 10,000              
Collaboration to Develop IONIS-FB-L with Roche [Member]                    
Revenue Recognition [Abstract]                    
Revenue 35,000 $ 13,800                
Upfront payment received           $ 75,000        
Milestone payment received and added to transaction price   $ 20,000                
Neurology Collaborations with Biogen [Member]                    
Revenue Recognition [Abstract]                    
Revenue $ 13,000                  
Number of targets advanced | Target 2                  
Alnylam [Member]                    
Revenue Recognition [Abstract]                    
Revenue         $ 41,200          
Eplontersen Collaboration with AstraZeneca [Member]                    
Revenue Recognition [Abstract]                    
Revenue                   $ 200,000
Number of material components | Component                   4
Number of separate performance obligations | PerformanceObligation                   1
Transaction price                   $ 200,000
Percentage of costs associated with ongoing global Phase 3 development program paid by AstraZeneca               55.00%